This site is intended for health professionals only!

Published on 10 August 2009

Share this story:
Twitter
LinkedIn

Combined arthritis treatment hailed

teaser

Methotrexate monotherapy plus a tumour necrosis factor (TNF) antagonist such as infliximab is the best treatment for early rheumatoid arthritis (RA), according to trials.

Antagonists like infliximab and conventional disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine and hydroxychloroquine are better than methotrexate alone, according to a report in The Lancet.

Tests by Ronald van Vollenhoven and colleagues at the Karolinska University Hospital and Karolinska Institute in Sweden involved 487 patients with early RA of less than 1 year’s duration.

After three to four months treatment with methotrexate alone, patients also receive either infliximab or sulfasalazine and hydroxychloroquine.

After 12 months, 25% of patients given sulfasalazine and hydroxychloroquine and 39% of patients given infliximab achieved a good response, as judged by European League Against Rheumatism (EULAR) scores.

The authors conclude: “We believe that by treating all patients with methotrexate for 3-4 months, we screened out a sizeable proportion (30% in this trial) who would have been overtreated if aggressive combination therapy was used for all, an approach that could have increased the risk of side-effects and potentially entailed high costs.”

Copyright Press Association 2009

The Lancet



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn